Stay updated on FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Sign up to get notified when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.

Latest updates to the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe changes consist of an internal software revision update from v3.4.1 to v3.4.2; no content related to the study details, eligibility, or results appears to be altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1; this is a minor metadata change with no impact on the study details or functionality.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.3.3 updated to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded a Results Submitted status and expanded the Locations section to include multiple study sites across the United States and Australia. The expanded location list includes Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Texas, Washington, Victoria, and Western Australia.SummaryDifference2%

- Check94 days agoChange DetectedThe page now shows an updated revision label: v3.3.2, replacing the previous v3.2.0.SummaryDifference0.0%

- Check102 days agoChange DetectedThe funding-status notice that previously appeared on the ClinicalTrials.gov page was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to FLX475 Dose Escalation Trial in Combination With Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the FLX475 Dose Escalation Trial in Combination With Pembrolizumab page.